Dendritic cell based vaccines: Progress in immunotherapy studies for prostate cancer

Journal of Urology

Volumn 172, Issue 6 II, 2004, Pages 2532-2538

  Ragde, Haakon ^a   Cavanagh, William A ^a   Tjoa, Benjamin A ^a  

^a Haakon Ragde Found Adv Cancer S   (United States)

Author keywords

Clinical trials; Dendritic cells; Immunotherapy; Prostatic neoplasms; Vaccines

Indexed keywords

CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL DIFFERENTIATION; CELL LINE; CELL MATURATION; CHILL; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; FATIGUE; FEVER; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; LYMPHADENOPATHY; MEDICAL LITERATURE; NONHUMAN; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; SIDE EFFECT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VACCINATION; VITILIGO;

EID: 8644259104     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000144211.51111.e4     Document Type: Conference Paper

References (90)

1. Hanks, G. E., Krall, J. M., Hanlon, A. L., Asbell, S. O., Pilepich, M. V. and Owen, J. B.: Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int J Radiat Oncol Biol Phys, 28: 39, 1994
2. Middleton, R. G., Smith, J. A., Jr., Melzer, R. B. and Hamilton, P. E.: Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J Urol, 136: 422, 1986
3. Walsh, P. C., Partin, A. W. and Epstein, J. I.: Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol, 152: 1831, 1994
4. Jones, G. W., Mettlin, C., Murphy, G. P., Guinan, P., Herr, H. W., Hussey, D. H. et al: Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg, 180: 545, 1995
5. Iversen, P.: Orchidectomy and oestrogen therapy revisited. Eur Urol, 34: 7, 1998
6. Scher, H. I., Steineck, G. and Kelly, W. K.: Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 46: 142, 1995
7. Oh, W. K. and Kantoff, P. W.: Management of hormone refractory prostate cancer: current standards and future prospects. J Urol, 160: 1220, 1998
8. Ada, G. L.: The immunological principles of vaccination. Lancet, 335: 523, 1990
9. Coley, W. B.: The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases (1893). Clin Orthop, 273: 3, 1991
10. Robbins, P. F. and Kawakami, Y.: Human tumor antigens recognized by T cells. Curr Opin Immunol, 8: 628, 1996
11. Urban, J. L. and Schreiber, H.: Tumor antigens. Ann Rev Immunol, 10: 617, 1992
12. Vonderheide, R. H., Hahn, W. C., Schultze, J. L. and Nadler, L. M.: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity, 10: 673, 1999
13. Theobald, M., Biggs, J., Dittmer, D., Levine, A. J. and Sherman, L. A.: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA, 92: 11993, 1995
14. Wolfel, T., Hauer, M., Schneider, J., Serrano, M., Wolfel, C., Klehmann-Hieb, E. et al: A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269: 1281, 1995
15. Bocchia, M., Bronte, V., Colombo, M. P., De Vincentiis, A., Di Nicola, M., Forni, G. et al: Antitumor vaccination: where we stand. Haematologica, 85: 1172, 2000
16. Brichard, V., Van Pel, A., Wolfel, T., Wolfel, C., De Plaen, E., Lethe, B. et al: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med, 178: 489, 1993
17. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Rivoltini, L., Topalian, S. L. et al: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA, 91: 3515, 1994
18. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E. et al: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA, 91: 6458, 1994
19. Fair, W. R., Israeli, R. S. and Heston, W. D.: Prostate-specific membrane antigen. Prostate, 32: 140, 1997
20. Wang, M. C., Papsidero, L. D., Kuriyama, M., Valenzuela, L. A., Murphy, G. P. and Chu, T. M.: Prostate antigen: a new potential marker for prostatic cancer. Prostate, 2: 89, 1981
21. Marrack, P., Enders, R., Shimonkevitz, R., Zlotnik, A., Dialynas, D., Fitch, F. et al: The major histocompatibility complex-restricted antigen receptor on T cells. II. Role of the L3T4 product. J Exp Med, 158: 1077, 1983
22. Janeway, C. A., Jr. and Bottomly, K.: Signals and signs for lymphocyte responses. Cell, 76: 275, 1994
23. Banchereau, J. and Steinman, R. M.: Dendritic cells and the control of immunity. Nature, 392: 245, 1998
24. Steinman, R. M. and Cohn, Z. A.: Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med, 137: 1142, 1973
25. Zhou, L. J. and Tedder, T. F.: Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol, 154: 3821, 1995
26. Freudenthal, P. S. and Steinman, R. M.: The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA, 87: 7698, 1990
27. Steinman, R. M.: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol, 9: 271, 1991
28. Tulp, A., Verwoerd, D., Dobberstein, B., Ploegh, H. L. and Pieters, J.: Isolation and characterization of the intracellular MHC class II compartment. Nature, 369: 120, 1994
29. Jondal, M., Schirmbeck, R. and Reimann, J.: MHC class I-restricted CTL responses to exogenous antigens. Immunity, 5: 295, 1996
30. Albert, M. L., Pearce, S. F., Francisco, L. M., Sauter, B., Roy, P., Silverstein, R. L. et al: Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med, 188: 1359, 1998
31. Bennett, S. R., Carbone, F. R., Karamalis, F., Miller, J. F. and Heath, W. R.: Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med, 186: 65, 1997
32. Sallusto, F. and Lanzavecchia, A.: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med, 179: 1109, 1994
33. Thurner, B., Roder, C., Dieckmann, D., Heuer, M., Kruse, M., Glaser, A. et al: Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods, 223: 1, 1999
34. Berger, T. G., Feuerstein, B., Strasser, E., Hirsch, U., Schreiner, D., Schuler, G. et al: Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods, 268: 131, 2002
35. Guyre, C. A., Fisher, J. L., Waugh, M. G., Wallace, P. K., Tretter, C. G., Ernstoff, M. S. et al: Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods, 262: 85, 2002
36. Rouard, H., Leon, A., De Reys, S., Taylor, L., Logan, J., Marquet, J. et al: A closed and single-use system for monocyte enrichment: potential for dendritic cell generation for clinical applications. Transfusion, 43: 481, 2003
37. Pullarkat, V., Lau, R., Lee, S. M., Bender, J. G. and Weber, J. S.: Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods, 267: 173, 2002
38. Goxe, B., Latour, N., Bartholeyns, J., Romet-Lemonne, J. L. and Chokri, M.: Monocyte-derived dendritic cells: development of a cellular processor for clinical applications. Res Immunol, 149: 643, 1998
39. Zhou, Y., Monahan, S., Turner, A., McEarchern, J., Harris, P. and Bosch, M. L.: Commercial scale production of dendritic cells for cancer immunotherapy. Proc Am Assoc Cancer Res, 44: 2876A, 2003
40. Terasawa, H., Tsang, K. Y., Gulley, J., Arlen, P. and Schlom, J.: Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen. Clin Cancer Res, 8: 41, 2002
41. Chakraborty, N. G., Stevens, R. L., Mehrotra, S., Laska, E., Taxel, P., Sporn, J. R. et al: Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother, 52: 497, 2003
42. Horiguchi, Y., Nukaya, I., Okazawa, K., Kawashima, I., Fikes, J., Sette, A. et al: Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes. Clin Cancer Res, 8: 3885, 2002
43. Tjoa, B., Boynton, A., Kenny, G., Ragde, H., Misrock, S. L. and Murphy, G.: Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate, 28: 65, 1996
44. Peshwa, M. V., Shi, J. D., Ruegg, C., Laus, R. and van Schooten, W. C.: Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate, 36: 129, 1998
45. Kiessling, A., Schmitz, M., Stevanovic, S., Weigle, B., Holig, K., Fussel, M. et al: Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer, 102: 390, 2002
46. Kiessling, A., Fussel, S., Schmitz, M., Stevanovic, S., Meye, A., Weigle, B. et al: Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate, 56: 270, 2003
47. Correale, P., Micheli, L., Veccnio, M. T., Sabatino, M., Petrioli, R., Pozzessere, D. et al: A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Br J Cancer, 85: 1722, 2001
48. Ribas, A., Bui, L. A., Butterfield, L. H., Vollmer, C. M., Jilani, S. M., Dissette, V. B. et al: Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res, 19: 1165, 1999
49. Liau, L. M., Black, K. L., Prins, R. M., Sykes, S. N., DiPatre, P. L., Cloughesy, T. F. et al: Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg, 90: 1115, 1999
50. Enders, G. A.: Mechanism of antigen presentation after hypertonic loading of soluble antigens. Immunology, 106: 511, 2002
51. Kim, K. W., Kim, S. H., Jang, J. H., Lee, E. Y., Park, S. W., Um, J. H. et al: Dendritic cells loaded with exogenous antigen by electroporation can enhance MHC class I-mediated antitumor immunity. Cancer Immunol Immunother, 2003
52. Berlyn, K. A., Schultes, B., Leveugle, B., Noujaim, A. A., Alexander, R. B. and Mann, D. L.: Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen/antibody) complexes. Clin Immunol, 101: 276, 2001
53. Okada, N., Saito, T., Mori, K., Masunaga, Y., Fujii, Y., Fujita, J. et al: Effects of lipofectin-antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. Biochim Biophys Acta, 1527: 97, 2001
54. Robson, N. C., Beacock-Sharp, H., Donachie, A. M. and Mowat, A. M.: Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading. Immunology, 109: 374, 2003
55. Rescigno, M., Valzasina, B., Bonasio, R., Urbano, M. and Ricciardi-Castagnoli, P.: Dendritic cells, loaded with recombinant bacteria expressing tumor antigens, induce a protective tumor-specific response. Clin Cancer Res, 7: 865s, 2001
56. Rini, B. I.: Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther, 4: 76, 2002
57. Reeves, M. E., Royal, R. E., Lam, J. S., Rosenberg, S. A. and Hwu, P.: Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res, 56: 5672, 1996
58. Zhong, L., Granelli-Piperno, A., Choi, Y. and Steinman, R. M.: Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol, 29: 964, 1999
59. Boczkowski, D., Nair, S. K., Snyder, D. and Gilboa, E.: Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med, 184: 465, 1996
60. Heiser, A., Dahm, P., Yancey, D. R., Maurice, M. A., Boczkowski, D., Nair, S. K. et al: Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. J Immunol, 164: 5508, 2000
61. Nair, S. K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J. S. et al: Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med, 6: 1011, 2000
62. Heiser, A., Maurice, M. A., Yancey, D. R., Wu, N. Z., Dahm, P., Pruitt, S. K. et al: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol, 166: 2953, 2001
63. Triozzi, P. L., Khurram, R., Aldrich, W. A., Walker, M. J., Kim, J. A. and Jaynes, S.: Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer, 89: 2646, 2000
64. Nikitina, E. Y. and Gabrilovich, D. I.: Combination of gamma-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int J Cancer, 94: 825, 2001
65. Tanaka, F., Yamaguchi, H., Ohta, M., Mashino, K., Sonoda, H., Sadanaga, N. et al: Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer, 101: 265, 2002
66. Onaitis, M., Kalady, M. F., Pruitt, S. and Tyler, D. S.: Dendritic cell gene therapy. Surg Oncol Clin North Am, 11: 645, 2002
67. Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C. et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol, 166: 678, 2001
68. Zhou, L. J. and Tedder, T. F.: CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA, 93: 2588, 1996
69. Romani, N., Reider, D., Heuer, M., Ebner, S., Kampgen, E., Eibl, B. et al: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods, 196: 137, 1996
70. Rieser, C., Bock, G., Klocker, H., Bartsch, G. and Thurnher, M.: Prostaglandin E2 and tumor necrosis factor alpha cooperate to activate human dendritic cells: synergistic activation of interleukin 12 production. J Exp Med, 186: 1603, 1997
71. Delneste, Y., Herbault, N., Galea, B., Magistrelli, G., Bazin, I., Bonnefoy, J. Y. et al: Vasoactive intestinal peptide synergizes with TNF-alpha in inducing human dendritic cell maturation. J Immunol, 163: 3071, 1999
72. Verdijk, R. M., Mutis, T., Esendam, B., Kamp, J., Melief, C. J., Brand, A. et al: Polyriboinosinic polyribocytidylic acid (poly(I: C)) induces stable maturation of functionally active human dendritic cells. J Immunol, 163: 57, 1999
73. De Smedt, T., Pajak, B., Muraille, E., Lespagnard, L., Heinen, E., De Baetselier, P. et al: Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med, 184: 1413, 1996
74. Thurnher, M., Ramoner, R., Gastl, G., Radmayr, C., Bock, G., Herold, M. et al: Bacillus Calmette-Guerin mycobacteria stimulate human blood dendritic cells. Int J Cancer, 70: 128, 1997
75. Kennedy, M. K., Picha, K. S., Shanebeck, K. D., Anderson, D. M. and Grabstein, K. H.: Interleukin-12 regulates the prolifera tion of Th1, but not Th2 or Th0, clones. Eur J Immunol, 24: 2271, 1994
76. Fiorentino, D. F., Bond, M. W. and Mosmann, T. R.: Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med, 170: 2081, 1989
77. Pardoll, D. M.: Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol, 2: 227, 2002
78. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S. et al: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med, 170: 827, 1989
79. Voest, E. E., Kenyon, B. M., O'Reilly, M. S., Truitt, G., D'Amato, R. J. and Folkman, J.: Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst, 87: 581, 1995
80. Snijders, A., Kalinski, P., Hilkens, C. M. and Kapsenberg, M. L.: High-level IL-12 production by human dendritic cells requires two signals. Int Immunol, 10: 1593, 1998
81. Shankar, G., Pestano, L. A. and Bosch, M. L.: Interferon-gamma added during bacillus Calmette-Guerin induced dendritic cell maturation stimulates potent Th1 immune responses. J Transl Med, 1: 7, 2003
82. Mukherji, B., Chakraborty, N. G., Yamasaki, S., Okino, T., Yamase, H., Sporn, J. R. et al: Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells. Proc Natl Acad Sci USA, 92: 8078, 1995
83. Ridgway, D.: The first 1000 dendritic cell vaccinees. Cancer Invest, 21: 873, 2003
84. Murphy, G., Tjoa, B., Ragde, H., Kenny, G. and Boynton, A.: Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate, 29: 371, 1996
85. Tjoa, B. A., Lodge, P. A., Salgaller, M. L., Boynton, A. L. and Murphy, G. P.: Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin, 49: 117, 1999
86. Small, E. J., Fratesi, P., Reese, D. M., Strang, G., Laus, R., Peshwa, M. V. et al: Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol, 18: 3894, 2000
87. Burch, P. A., Breen, J. K., Buckner, J. C., Gastineau, D. A., Kaur, J. A., Laus, R. L. et al: Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res, 6: 2175, 2000
88. Fong, L., Brockstedt, D., Benike, C., Breen, J. K., Strang, G., Ruegg, C. L. et al: Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol, 167: 7150, 2001
89. Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D. et al: Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest, 109: 409, 2002
90. Vonderheide, R. H., Domchek, S. M., Schultze, J. L., George, D. J., Hoar, K. M., Chen, D. Y. et al: Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res, 10: 828, 2004